GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » United Laboratories International Holdings Ltd (FRA:UNJ) » Definitions » Return-on-Tangible-Equity

United Laboratories International Holdings (FRA:UNJ) Return-on-Tangible-Equity : 23.55% (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is United Laboratories International Holdings Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. United Laboratories International Holdings's annualized net income for the quarter that ended in Dec. 2023 was €364 Mil. United Laboratories International Holdings's average shareholder tangible equity for the quarter that ended in Dec. 2023 was €1,545 Mil. Therefore, United Laboratories International Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was 23.55%.

The historical rank and industry rank for United Laboratories International Holdings's Return-on-Tangible-Equity or its related term are showing as below:

FRA:UNJ' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -4.9   Med: 10.37   Max: 23.33
Current: 23.33

During the past 13 years, United Laboratories International Holdings's highest Return-on-Tangible-Equity was 23.33%. The lowest was -4.90%. And the median was 10.37%.

FRA:UNJ's Return-on-Tangible-Equity is ranked better than
85.71% of 938 companies
in the Drug Manufacturers industry
Industry Median: 6.475 vs FRA:UNJ: 23.33

United Laboratories International Holdings Return-on-Tangible-Equity Historical Data

The historical data trend for United Laboratories International Holdings's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Laboratories International Holdings Return-on-Tangible-Equity Chart

United Laboratories International Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.48 9.29 11.71 15.85 22.83

United Laboratories International Holdings Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.33 13.48 18.53 22.88 23.55

Competitive Comparison of United Laboratories International Holdings's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, United Laboratories International Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Laboratories International Holdings's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, United Laboratories International Holdings's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where United Laboratories International Holdings's Return-on-Tangible-Equity falls into.



United Laboratories International Holdings Return-on-Tangible-Equity Calculation

United Laboratories International Holdings's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=346.928/( (1421.403+1617.906 )/ 2 )
=346.928/1519.6545
=22.83 %

United Laboratories International Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=363.926/( (1472.988+1617.906)/ 2 )
=363.926/1545.447
=23.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


United Laboratories International Holdings  (FRA:UNJ) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


United Laboratories International Holdings Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of United Laboratories International Holdings's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


United Laboratories International Holdings (FRA:UNJ) Business Description

Traded in Other Exchanges
Address
No. 6 Fuk Wang Street, Yuen Long Industrial Estate, New Territories, Hong Kong, HKG
United Laboratories International Holdings Ltd is a major drug manufacturing company. United Laboratories is organized into three revenue streams, including Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Bulk medicine segment, followed by Finished products. Most of the company's sales are generated in China, followed by Europe and India.

United Laboratories International Holdings (FRA:UNJ) Headlines

No Headlines